Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials
Conventional randomized controlled trials (RCTs) can be expensive, time intensive, and
complex to conduct. Trial recruitment, participation, and data collection can burden …
complex to conduct. Trial recruitment, participation, and data collection can burden …
Disparities in cardiovascular care and outcomes for women from racial/ethnic minority backgrounds
S Balla, SE Gomez, F Rodriguez - Current treatment options in …, 2020 - Springer
Purpose of review Racial, ethnic, and gender disparities in cardiovascular care are well-
documented. This review aims to highlight the disparities and impact on a group particularly …
documented. This review aims to highlight the disparities and impact on a group particularly …
Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank
KA Krychtiuk, TLG Andersson, U Bodesheim… - American Heart …, 2024 - Elsevier
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases
due to more predictable development pathways and financial incentives. In contrast, drug …
due to more predictable development pathways and financial incentives. In contrast, drug …
Design of clinical trials evaluating sedation in critically Ill adults undergoing mechanical ventilation: recommendations from sedation consortium on endpoints and …
OBJECTIVES: Clinical trials evaluating the safety and effectiveness of sedative medication
use in critically ill adults undergoing mechanical ventilation differ considerably in their …
use in critically ill adults undergoing mechanical ventilation differ considerably in their …
3D printed nanocomposites for tailored cardiovascular tissue constructs: A minireview
Cardiovascular diseases (CVD) with escalating death rates pose one of the greatest threats
to global health and well-being. Thus, developing effective interventions to combat CVD are …
to global health and well-being. Thus, developing effective interventions to combat CVD are …
[HTML][HTML] A systematic review of models of patient engagement in the development and life cycle management of medicines
FI Auwal, C Copeland, EJ Clark, C Naraynassamy… - Drug Discovery …, 2023 - Elsevier
There is currently no universally agreed code of practice for patient engagement (PE), and
existing guidelines do not fully cover the scope across medicine development and …
existing guidelines do not fully cover the scope across medicine development and …
The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European …
R Jandhyala - Journal of Pharmaceutical Policy and Practice, 2022 - Springer
Background Despite calls for the use of additional real-world evidence (RWE) during drug
development, rates of inclusion at the regulatory stage remain low. The medicine adoption …
development, rates of inclusion at the regulatory stage remain low. The medicine adoption …
The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease
EVP Espinosa, EM Matute, DM Sosa Guzmán… - Journal of Clinical …, 2024 - mdpi.com
Cardiovascular disease (CVD) is the primary cause of death and disability worldwide.
Although age-standardized CVD mortality rates decreased globally by 14.5% between 2006 …
Although age-standardized CVD mortality rates decreased globally by 14.5% between 2006 …
Everything, Everywhere All at Once: Evidence Generation and Implementation in the Digital Age
AF Hernandez - Circulation: Cardiovascular Quality and Outcomes, 2024 - Am Heart Assoc
The challenge now is the sheer volume of data generated daily, with a single patient
contributing up to 80 megabytes yearly in imaging and electronic health data. 2 Hospitals …
contributing up to 80 megabytes yearly in imaging and electronic health data. 2 Hospitals …
Value in Healthcare Initiative: summary and key recommendations
In spring 2018, the American Heart Association convened the Value in Healthcare Summit to
begin an important conversation about the challenges patients with cardiovascular disease …
begin an important conversation about the challenges patients with cardiovascular disease …